Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. doi: 10.1093/neuonc/noac202.
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.71 per 100,000 population (malignant AAAIR=7.02 and non-malignant AAAIR=17.69). This overall rate was higher in females compared to males (27.62 versus 21.60 per 100,000) and non-Hispanic persons compared to Hispanic persons (25.09 versus 22.95 per 100,000). The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (14.2% of all tumors and 50.1% of all malignant tumors), and the most common non-malignant histopathology was meningioma (39.7% of all tumors and 55.4% of all non-malignant tumors). Glioblastoma was more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.20 per 100,000 population. An estimated 93,470 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2022 (26,670 malignant and 66,806 non-malignant). There were 84,264 deaths attributed to malignant brain and other CNS tumors between 2015 and 2019. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 16,853 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.7%, while for non-malignant brain and other CNS tumors the five-year relative survival rate was 91.8%.
美国中央脑肿瘤登记处（CBTRUS）与疾病控制与预防中心和国家癌症研究所合作，是美国（美国）唯一专注于原发性脑肿瘤和其他中枢神经系统（CNS）肿瘤的最大基于人群的登记处，代表了整个美国人口。本报告包含了最新的基于人群的原发性脑肿瘤数据，在完整性和准确性方面超过了以往所有报告。所有比率均使用 2000 年美国标准人口进行年龄调整，并以每 10 万人为单位呈现。所有恶性和非恶性脑和其他中枢神经系统肿瘤的平均年度年龄调整发病率（AAAIR）为每 10 万人 24.71 人（恶性 AAAIR=7.02，非恶性 AAAIR=17.69）。女性的总体发病率高于男性（每 10 万人 27.62 与 21.60），非西班牙裔人口高于西班牙裔人口（每 10 万人 25.09 与 22.95）。最常见的恶性脑和其他中枢神经系统组织病理学是胶质母细胞瘤（所有肿瘤的 14.2%和所有恶性肿瘤的 50.1%），最常见的非恶性组织病理学是脑膜瘤（所有肿瘤的 39.7%和所有非恶性肿瘤的 55.4%）。胶质母细胞瘤在男性中更为常见，脑膜瘤在女性中更为常见。在儿童和青少年（0-19 岁）中，所有原发性脑和其他中枢神经系统肿瘤的发病率为每 10 万人 6.20 人。估计 2022 年美国人口中将诊断出 93470 例新的恶性和非恶性脑和其他中枢神经系统肿瘤（26670 例恶性和 66806 例非恶性）。2015 年至 2019 年期间，有 84264 人死于恶性脑和其他中枢神经系统肿瘤。这代表每 10 万人每年平均死亡率为 4.41，平均每年死亡 16853 人。诊断出恶性脑和其他中枢神经系统肿瘤后的五年相对生存率为 35.7%，而非恶性脑和其他中枢神经系统肿瘤的五年相对生存率为 91.8%。
CA Cancer J Clin. 2021-9
Discov Oncol. 2025-9-3
Front Immunol. 2025-8-15
Cancer Genomics Proteomics. 2025
Cancers (Basel). 2025-8-15
Cancers (Basel). 2025-8-9
CA Cancer J Clin. 2022-1
Neuro Oncol. 2021-8-2
Neurooncol Pract. 2019-12
Neuro Oncol. 2020-2-20
J Registry Manag. 2016
Zotero 插件